Can Mounjaro be prescribed for weight loss?

The licence that allows Mounjaro to be prescribed for weight loss

NICE's appraisal of tirzepatide, published in December 2024 as TA1026, confirmed tirzepatide as an effective option for weight management and recommended it for NHS use under defined criteria. That sits on top of the MHRA marketing authorisation, which covers adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes. The licence is explicitly for weight management, it is not restricted to diabetes, which is a common point of confusion, partly because tirzepatide is also licensed for type 2 diabetes under the same brand name.

Mounjaro is a dual GIP and GLP-1 receptor agonist, which means it activates two gut-hormone pathways at once, reducing appetite and slowing gastric emptying. In SURMOUNT-1, a 72-week randomised trial involving 2,539 adults with obesity, participants on the 15 mg dose lost an average of around 20–21% of body weight. That evidence base is what underpins both the MHRA licence and the NICE recommendation. You can read the SURMOUNT-1 paper in the New England Journal of Medicine if you want the full data.

One practical note: treatment starts at 2.5 mg, a dose designed to let your system adjust, and is titrated upward by the prescriber over several months. The 2.5 mg pen is not where the therapeutic weight-loss results occur, patience through that early phase is part of the clinical plan.

Who meets the prescribing criteria and how that assessment works

The clinical criteria for a Mounjaro prescription follow the licence: adults aged 18 or over, BMI 30 or above, or BMI 27 or above with at least one qualifying weight-related condition. For some ethnic backgrounds, those thresholds sit 2.5 kg/m² lower under current UK guidance. Below those figures, a prescriber cannot lawfully prescribe for weight management.

BMI is a starting point, not a decision. A responsible prescriber also considers your medical history, current medicines, and whether any contraindications apply. Mounjaro is not suitable during pregnancy, whilst breastfeeding, or if you are trying to conceive. A history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 rules it out, and certain gastrointestinal conditions require careful discussion.

Understanding which doctors can prescribe Mounjaro is useful here: GPs, hospital physicians and GPhC-registered Independent Prescribers working in regulated online pharmacies can all issue this prescription. The route differs; the clinical standard does not. If you are thinking about whether your GP will prescribe it, that depends partly on whether your practice has joined the new GP contract weight-management scheme and whether you meet the NHS cohort criteria.

For most people reading this, the quicker route is a private consultation. There are no waiting lists, though the clinical bar is identical.

NHS prescribing versus a private prescription: what that means in practice

NHS prescribing of tirzepatide is being phased in by cohort. From June 2025, the NHS began prescribing for adults with a BMI of 40 or above alongside four or more of five specific conditions. A second cohort (BMI 35–39.9 with four or more of those conditions) opened in June 2026. Further cohorts are expected into 2027. The full NHS eligibility picture is worth reading if that route interests you.

A private prescription sits outside those phased criteria. Any adult meeting the licensed BMI threshold with no contraindications can be assessed. If the prescriber approves, the prescription is issued and the medicine dispensed. That assessment still has to be rigorous, the medicine is the same, the safety obligations are the same, and the prescription is just as legally binding. If you are curious about how private Mounjaro pricing varies across providers, that context is worth reading before you commit to a service.

One thing patients sometimes ask: can they get a prescription before payday, order mid-month, or pause between pens? The answer is yes, there are no subscription requirements on a well-run private service, and each prescription is re-reviewed before any repeat is issued. The clinical process applies every time, not just the first.

How to get Mounjaro prescribed for weight loss through a regulated service

The practical steps are straightforward. You complete a clinical consultation, detailed health questions reviewed by a GPhC-registered Independent Prescriber, not automated software. Photo-ID verification and live weight confirmation happen at this stage. If the prescriber is satisfied that the clinical criteria are met, they issue the prescription; if not, they explain why and may suggest an alternative. There is no approval guarantee, and any service claiming otherwise should be avoided.

At nume (at our pharmacy) consultations are reviewed the same day, orders placed before noon on a weekday are dispatched the same day once approved, and delivery arrives free the next working day via DPD in plain packaging. Our clinical team reviews every consultation personally. If you want to understand more about how the Mounjaro prescribing process works end to end, that page covers it in detail.

Mounjaro is a Black Triangle medicine, meaning the MHRA monitors it closely for any emerging safety signals. Patients can report suspected side effects directly at the MHRA Yellow Card scheme. Any side effects should be discussed with your prescribing team, who remain responsible for your care throughout treatment, and if you ever need to stop the medicine our guide on how to get Mounjaro out of your system explains what to expect as it clears.

If you meet the criteria and want a clinical assessment, you can start your free consultation today.